PrEP 001 (Panviral Prophylaxis)
PrEP-001 is a nasally administered, broad spectrum agent that leverages the innate immune system to prevent upper respiratory tract viral infections. It is the flagship product of PrEP Biopharm, in which hVIVO acquired a significant equity stake in November 2015.
PrEP-001 is a prophylactic compound focussed on the common cold (human rhinovirus) and flu (influenza). It is a nasally administered, broad spectrum agent that leverages the innate immune system to prevent upper respiratory tract viral infections (colds and flus). This novel prophylactic nose spray delivers a benign surrogate for a respiratory virus into the nose which tricks the nasal lining cells into thinking they are being invaded by a real virus, which in turn activates the local innate immune defence system.
PrEP Biopharm Limited
PrEP BioPharm is a development stage biopharmaceutical company that is creating a fundamentally new paradigm of prophylaxis for upper respiratory tract infections.
In November 2015, hVIVO acquired a significant equity stake in PrEP Biopharm Limited (“PrEP Biopharm”) a new UK biotech company with its prophylactic compound PrEP-001, a compound where hVIVO’s platform has been a fundamental contributor to its success to date. This allows hVIVO to participate in the upside value generated by the product insights our platform provides. We are leveraging the platform’s speed of conduct for early phase research and application of its biological insights to simplify later phase studies – further enhancing PrEP-001’s potential going forward.
In 2014, hVIVO conducted a proof of concept study for Janssen using the hVIVO platform. This study demonstrated that Janssen’s compound (now renamed PrEP-001) achieved a threefold reduction in clinical illness and an eightfold reduction in common cold symptoms compared with a placebo. With these promising results, hVIVO saw tremendous commercial potential for PrEP-001.
Find out more about PrEP Biopharm Ltd. at http://www.prepbiopharm.com/.